170456-89-0

Basic information

• Product Name: 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole
• Synonyms: 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole
• CAS NO: 170456-89-0
• Molecular Weight: 294.398
• Mol File: 170456-89-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole(170456-89-0)
• EPA Substance Registry System: 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole(170456-89-0)

Safety Data

• Hazardous Substances Data: 170456-89-0(Hazardous Substances Data)

Upstream product

• 70-55-3 toluene-4-sulfonamide 
• 73696-28-3 1-[(4-methylphenyl)sulfonyl]pyrrolidin-3-one 
• 170456-88-9 2-methyl-5-(toluene-4-sulfonyl)-4,5,6,6a-tetrahydropyrrolo<4,3-d>thiazol-3a-ol 
• 170456-82-3 4-bromo-1-(p-toluenesulfonyl)pyrrolidin-3-one 
• 170456-83-4 1-tosyl-3-(R)-(-)-hydroxypyrrolidine 
• 16851-72-2 1-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-pyrrole 

Downstream Products

• 773031-79-1 2-methyl-5,6-dihydro-4H-pyrrolo[3,4-d]thiazole 

Relevant articles and documents

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.